vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and NELNET INC (NNI). Click either name above to swap in a different company.

Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $33.5M, roughly 1.3× NELNET INC). NELNET INC runs the higher net margin — 172.3% vs -23.3%, a 195.5% gap on every dollar of revenue. On growth, NELNET INC posted the faster year-over-year revenue change (79.6% vs 7.0%). Over the past eight quarters, NELNET INC's revenue compounded faster (62.0% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Nelnet, Inc. is a United States–based conglomerate that primarily focuses on financial services including student and consumer loan origination and servicing. Additionally, the company operates an investing arm, an internet bank and has a 26% stake in Allo Fiber, a cable and internet provider. The company is headquartered in Lincoln, Nebraska.

AMRN vs NNI — Head-to-Head

Bigger by revenue
AMRN
AMRN
1.3× larger
AMRN
$45.1M
$33.5M
NNI
Growing faster (revenue YoY)
NNI
NNI
+72.6% gap
NNI
79.6%
7.0%
AMRN
Higher net margin
NNI
NNI
195.5% more per $
NNI
172.3%
-23.3%
AMRN
Faster 2-yr revenue CAGR
NNI
NNI
Annualised
NNI
62.0%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
NNI
NNI
Revenue
$45.1M
$33.5M
Net Profit
$-10.5M
$57.8M
Gross Margin
50.5%
Operating Margin
35.5%
Net Margin
-23.3%
172.3%
Revenue YoY
7.0%
79.6%
Net Profit YoY
33.0%
-8.5%
EPS (diluted)
$1.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
NNI
NNI
Q1 26
$45.1M
Q4 25
$49.2M
$33.5M
Q3 25
$49.7M
$23.2M
Q2 25
$72.7M
$26.1M
Q1 25
$42.0M
$24.7M
Q4 24
$62.3M
$18.7M
Q3 24
$42.3M
$16.6M
Q2 24
$67.5M
$14.9M
Net Profit
AMRN
AMRN
NNI
NNI
Q1 26
$-10.5M
Q4 25
$-1.2M
$57.8M
Q3 25
$-7.7M
$106.7M
Q2 25
$-14.1M
$181.5M
Q1 25
$-15.7M
$82.6M
Q4 24
$-48.6M
$63.2M
Q3 24
$-25.1M
$2.4M
Q2 24
$1.5M
$45.1M
Gross Margin
AMRN
AMRN
NNI
NNI
Q1 26
Q4 25
47.1%
50.5%
Q3 25
44.7%
29.6%
Q2 25
69.2%
29.8%
Q1 25
59.8%
30.5%
Q4 24
-15.4%
13.7%
Q3 24
38.5%
0.1%
Q2 24
63.4%
27.3%
Operating Margin
AMRN
AMRN
NNI
NNI
Q1 26
35.5%
Q4 25
-12.9%
Q3 25
-22.4%
Q2 25
-22.0%
Q1 25
-39.9%
Q4 24
-84.3%
97.7%
Q3 24
-59.5%
-13.4%
Q2 24
-0.8%
88.0%
Net Margin
AMRN
AMRN
NNI
NNI
Q1 26
-23.3%
Q4 25
-2.5%
172.3%
Q3 25
-15.6%
460.5%
Q2 25
-19.4%
694.9%
Q1 25
-37.4%
334.4%
Q4 24
-78.0%
338.2%
Q3 24
-59.4%
14.4%
Q2 24
2.3%
303.6%
EPS (diluted)
AMRN
AMRN
NNI
NNI
Q1 26
Q4 25
$0.00
$1.62
Q3 25
$-0.02
$2.94
Q2 25
$-0.03
$4.97
Q1 25
$-0.04
$2.26
Q4 24
$-0.12
$1.74
Q3 24
$-0.06
$0.07
Q2 24
$0.00
$1.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
NNI
NNI
Cash + ST InvestmentsLiquidity on hand
$307.8M
$296.0M
Total DebtLower is stronger
$7.8B
Stockholders' EquityBook value
$3.7B
Total Assets
$645.8M
$14.1B
Debt / EquityLower = less leverage
2.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
NNI
NNI
Q1 26
$307.8M
Q4 25
$302.6M
$296.0M
Q3 25
$286.6M
$216.4M
Q2 25
$298.7M
$225.8M
Q1 25
$281.8M
$220.5M
Q4 24
$294.2M
$194.5M
Q3 24
$305.7M
$219.7M
Q2 24
$306.7M
$145.5M
Total Debt
AMRN
AMRN
NNI
NNI
Q1 26
Q4 25
$7.8B
Q3 25
$7.8B
Q2 25
$7.9B
Q1 25
$8.7B
Q4 24
$8.3B
Q3 24
$8.9B
Q2 24
$9.6B
Stockholders' Equity
AMRN
AMRN
NNI
NNI
Q1 26
Q4 25
$459.3M
$3.7B
Q3 25
$458.9M
$3.7B
Q2 25
$464.9M
$3.6B
Q1 25
$473.7M
$3.4B
Q4 24
$486.2M
$3.3B
Q3 24
$531.4M
$3.3B
Q2 24
$551.9M
$3.3B
Total Assets
AMRN
AMRN
NNI
NNI
Q1 26
$645.8M
Q4 25
$670.8M
$14.1B
Q3 25
$659.8M
$13.9B
Q2 25
$670.1M
$13.7B
Q1 25
$655.7M
$14.2B
Q4 24
$685.3M
$13.8B
Q3 24
$750.6M
$14.1B
Q2 24
$799.9M
$14.5B
Debt / Equity
AMRN
AMRN
NNI
NNI
Q1 26
Q4 25
2.11×
Q3 25
2.14×
Q2 25
2.21×
Q1 25
2.53×
Q4 24
2.48×
Q3 24
2.72×
Q2 24
2.90×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
NNI
NNI
Operating Cash FlowLast quarter
$423.0M
Free Cash FlowOCF − Capex
$396.7M
FCF MarginFCF / Revenue
1183.0%
Capex IntensityCapex / Revenue
78.2%
Cash ConversionOCF / Net Profit
7.32×
TTM Free Cash FlowTrailing 4 quarters
$663.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
NNI
NNI
Q1 26
Q4 25
$15.3M
$423.0M
Q3 25
$-12.7M
$112.4M
Q2 25
$16.6M
$81.8M
Q1 25
$-12.5M
$91.2M
Q4 24
$-13.3M
$662.9M
Q3 24
$-2.4M
$137.0M
Q2 24
$-2.7M
$133.8M
Free Cash Flow
AMRN
AMRN
NNI
NNI
Q1 26
Q4 25
$396.7M
Q3 25
$100.8M
Q2 25
$78.1M
Q1 25
$87.8M
Q4 24
$642.0M
Q3 24
$132.6M
Q2 24
$123.1M
FCF Margin
AMRN
AMRN
NNI
NNI
Q1 26
Q4 25
1183.0%
Q3 25
435.0%
Q2 25
299.0%
Q1 25
355.6%
Q4 24
3438.0%
Q3 24
797.9%
Q2 24
829.2%
Capex Intensity
AMRN
AMRN
NNI
NNI
Q1 26
Q4 25
78.2%
Q3 25
50.4%
Q2 25
14.2%
Q1 25
13.7%
Q4 24
111.9%
Q3 24
26.7%
Q2 24
71.5%
Cash Conversion
AMRN
AMRN
NNI
NNI
Q1 26
Q4 25
7.32×
Q3 25
1.05×
Q2 25
0.45×
Q1 25
1.10×
Q4 24
10.50×
Q3 24
57.39×
Q2 24
-1.81×
2.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

NNI
NNI

Segment breakdown not available.

Related Comparisons